Rune Labs

Rune Labs is a software and data analytics company focused on precision neurology, headquartered in San Francisco, California. Founded in October 2018, the company builds technology that connects neurophysiological data, patient-reported outcomes, and clinical interventions in order to improve care delivery and accelerate therapy development. Its stated mission is to make clinical brain data useful while keeping patients at the center of the process. The company's flagship offering is StrivePD, a care delivery ecosystem for Parkinson's disease. StrivePD collects symptom data — including through Apple Watch — and provides clinicians with curated dashboards that summarize multiple patient data sources, while also connecting patients to clinical trials. In June 2022, Rune Labs secured FDA 510(k) clearance for Parkinson's disease monitoring through the StrivePD ecosystem on Apple Watch. The company has also launched StriveStudy, a clinical trial platform intended to accelerate the development of precision neurology therapies. Rune Labs serves two main audiences: clinicians and patients on the care delivery side, and life sciences companies on the therapy development side. Its collaborations include work with BlueRock Therapeutics to better characterize Parkinson's disease state in cell therapy trials, and a program with Kaiser Permanente that reportedly nearly halved emergency room visits for Parkinson's patients. Beyond Parkinson's disease, the company is expanding into other neurodegenerative and neurological conditions including Multiple Sclerosis (MS), OCD, and Essential Tremor, where it is working on quantitative biomarkers and wearable data capture. Rune Labs is a privately held company. It closed a $5 million seed financing round led by DigiTx Partners in October 2020, a $22.8 million Series A round led by Eclipse Ventures in September 2021, and a $12 million strategic round in January 2024 to accelerate adoption of novel Parkinson's disease technologies. The company remains active and continues to develop its precision neurology platform.

Rune Labs was founded in San Francisco in October 2018, according to the company's own timeline. The company was established with the goal of making clinical brain data useful, with an explicit emphasis on keeping patients — the owners of those brains — at the center of its work. Its founding coincided with a period of rapid growth in neurotechnology, including the 2013 FDA approval of the NeuroPace RNS system (the world's first responsive deep brain stimulation device) and the 2016 founding of Neuralink, both of which the company lists as context in its timeline. In October 2020, Rune Labs closed a $5 million seed financing round led by DigiTx Partners. This early funding supported the development of its software and data analytics platform for precision neurology. A year later, in September 2021, the company closed a $22.8 million Series A round led by Eclipse Ventures, providing capital to expand its care delivery and therapy development offerings. A major milestone came in June 2022, when Rune Labs secured FDA 510(k) clearance for Parkinson's disease monitoring through its StrivePD ecosystem on Apple Watch. This clearance allowed the company to collect Parkinson's symptom data via a consumer wearable, a significant step for digital neurology. In March 2023, Rune Labs launched StriveStudy, a clinical trial platform designed to accelerate the development of precision neurology therapies. The platform supports life sciences companies in running trials with richer, more objective data. In January 2024, Rune Labs unveiled a $12 million strategic round to accelerate the adoption of novel Parkinson's disease technologies. Around this time, the company also reported results from a program with Kaiser Permanente that nearly halved emergency room visits for Parkinson's patients, demonstrating the potential of its care delivery model. Rune Labs has also collaborated with BlueRock Therapeutics to better characterize Parkinson's disease state in cell therapy trials. While the company started with Parkinson's disease, it has stated its intention to expand into other neurodegenerative and neurological conditions, including Multiple Sclerosis (MS), OCD, and Essential Tremor. It is working on identifying quantitative biomarkers of MS lesions and capturing symptoms and wearable data in OCD research. As of its latest public updates, Rune Labs remains a privately held, active company headquartered in San Francisco.

• Rune Labs is founded in San Francisco

• Rune Labs closes $5M Seed Financing round led by DigiTx Partners

• Rune Labs closes $22.8M Series A round led by Eclipse Ventures

• Rune Labs Secures FDA Clearance for Parkinson's Disease Monitoring through StrivePD Ecosystem on Apple Watch

• Rune Labs launches StriveStudy, a clinical trial platform accelerating development of precision neurology therapies

• Rune Labs unveils $12M strategic round to accelerate adoption of novel PD technologies

Precision neurology software and data analytics for care delivery and therapy development.

• StrivePD

  Care delivery ecosystem for Parkinson's disease that collects symptom data, including via Apple Watch, and provides clinicians with curated dashboards and connects patients to clinical trials.

• StriveStudy

  Clinical trial platform launched in March 2023 to accelerate development of precision neurology therapies.

• 2021-09-16

  Rune Labs announces $22.8 million Series A financing[4]Rune Labs 宣布完成 2,280 万美元 A 轮融资prnewswire.com

  Reported: 2021-09-16

  Rune Labs announced a $22.8 million Series A financing led by Eclipse Ventures, with participation from current investors including DigiTx Partners and Moment Ventures.

1. 1Rune Labsrunelabs.io
2. 2Rune Labs - About Usrunelabs.io
3. 3Rune Labs (United States) - Wikidatawikidata.org
4. 4Rune Labs 宣布完成 2,280 万美元 A 轮融资prnewswire.com